These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11137255)

  • 1. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines.
    Rimmelzwaan GF; Nieuwkoop N; Brandenburg A; Sutter G; Beyer WE; Maher D; Bates J; Osterhaus AD
    Vaccine; 2000 Dec; 19(9-10):1180-7. PubMed ID: 11137255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).
    Ennis FA; Cruz J; Jameson J; Klein M; Burt D; Thipphawong J
    Virology; 1999 Jul; 259(2):256-61. PubMed ID: 10388649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use.
    Deliyannis G; Jackson DC; Dyer W; Bates J; Coulter A; Harling-McNabb L; Brown LE
    Vaccine; 1998 Dec; 16(20):2058-68. PubMed ID: 9796065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.
    Sambhara S; Kurichh A; Miranda R; Tumpey T; Rowe T; Renshaw M; Arpino R; Tamane A; Kandil A; James O; Underdown B; Klein M; Katz J; Burt D
    Cell Immunol; 2001 Aug; 211(2):143-53. PubMed ID: 11591118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ISCOM-matrix-based equine influenza (EIV) vaccine stimulates cell-mediated immunity in the horse.
    Paillot R; Prowse L
    Vet Immunol Immunopathol; 2012 Jan; 145(1-2):516-21. PubMed ID: 22178272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In previously immunized elderly adults inactivated influenza A (H1N1) virus vaccines induce poor antibody responses that are not enhanced by liposome adjuvant.
    Powers DC; Hanscome PJ; Pietrobon PJ
    Vaccine; 1995 Oct; 13(14):1330-5. PubMed ID: 8585289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
    van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
    Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection, systemic IFNgamma, and antibody responses induced by an ISCOM-based vaccine against a recent equine influenza virus in its natural host.
    Paillot R; Grimmett H; Elton D; Daly JM
    Vet Res; 2008; 39(3):21. PubMed ID: 18252187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic T lymphocyte responses to a liposome-adjuvanted influenza A virus vaccine in the elderly.
    Powers DC; Manning MC; Hanscome PJ; Pietrobon PJ
    J Infect Dis; 1995 Oct; 172(4):1103-7. PubMed ID: 7561189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza (H1N1)-ISCOMs enhance immune responses and protection in aged mice.
    Sambhara S; Woods S; Arpino R; Kurichh A; Tamane A; Bengtsson KL; Morein B; Underdown B; Klein M; Burt D
    Mech Ageing Dev; 1997 Jun; 96(1-3):157-69. PubMed ID: 9223118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms) and oil-in-water vaccines.
    Coulter A; Wong TY; Drane D; Bates J; Macfarlan R; Cox J
    Vaccine; 1998 Jul; 16(11-12):1243-53. PubMed ID: 9682385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective Respiratory CD8 T-Cell Immunity to Influenza Virus Induced by Intranasal Carbomer-Lecithin-Adjuvanted Non-replicating Vaccines.
    Gasper DJ; Neldner B; Plisch EH; Rustom H; Carrow E; Imai H; Kawaoka Y; Suresh M
    PLoS Pathog; 2016 Dec; 12(12):e1006064. PubMed ID: 27997610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine.
    Powers DC; Belshe RB
    J Infect Dis; 1993 Mar; 167(3):584-92. PubMed ID: 8440930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction of the haemagglutinin transmembrane region in the influenza virus matrix protein facilitates its incorporation into ISCOM and activation of specific CD8(+) cytotoxic T lymphocytes.
    Voeten JT; Rimmelzwaan GF; Nieuwkoop NJ; Lövgren-Bengtsson K; Osterhaus AD
    Vaccine; 2000 Oct; 19(4-5):514-22. PubMed ID: 11027816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine.
    Polakos NK; Drane D; Cox J; Ng P; Selby MJ; Chien D; O'Hagan DT; Houghton M; Paliard X
    J Immunol; 2001 Mar; 166(5):3589-98. PubMed ID: 11207320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenicity and immunogenicity of experimental equine influenza ISCOM vaccines.
    Mumford JA; Jessett D; Dunleavy U; Wood J; Hannant D; Sundquist B; Cook RF
    Vaccine; 1994 Jul; 12(9):857-63. PubMed ID: 7975864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single dose of an ISCOM influenza vaccine induces long-lasting protective immunity against homologous challenge infection but fails to protect Cynomolgus macaques against distant drift variants of influenza A (H3N2) viruses.
    Rimmelzwaan GF; Baars M; van Amerongen G; van Beek R; Osterhaus AD
    Vaccine; 2001 Oct; 20(1-2):158-63. PubMed ID: 11567760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F; Vaman T; Gerlach B; Markendorf A; Gillard P; Devaster JM
    Vaccine; 2010 Feb; 28(7):1740-5. PubMed ID: 20034605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial.
    van Doorn E; Pleguezuelos O; Liu H; Fernandez A; Bannister R; Stoloff G; Oftung F; Norley S; Huckriede A; Frijlink HW; Hak E
    BMC Infect Dis; 2017 Apr; 17(1):241. PubMed ID: 28376743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.